Sign In
Buy URGN
$38.56
-1.67 (-4.15%)
At Close: Jul 10, 2026
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
02:11pm, Sunday, 12'th Jul 2026
According to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds. The sale represented 8% of the insider's direct equity hold
FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026 UGN-501 is a differen
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?
01:01pm, Tuesday, 07'th Jul 2026
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
11:38pm, Tuesday, 30'th Jun 2026
10,000 shares were sold for a transaction value of ~$350,000 at a weighted average price of around $35.01 per share on June 22, 2026. The sale represented 7.15% of Mark Schoenberg's direct holdings, r
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
11:14am, Sunday, 14'th Jun 2026
5,222 shares were sold on June 8, 2026 for a transaction value of approximately $143,000 at a weighted average price around $27.30 per share. The transaction represented 3.60% of Mark Schoenberg's dir
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:42pm, Wednesday, 10'th Jun 2026
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 05'th Jun 2026
PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
08:00am, Tuesday, 02'nd Jun 2026
Agreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolio Teva will be granted a non-exclusive license to sell its generic versio
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
04:10pm, Monday, 01'st Jun 2026
PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript
02:30pm, Sunday, 17'th May 2026
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript
PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
01:20pm, Wednesday, 13'th May 2026
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
08:00am, Wednesday, 13'th May 2026
64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FDA-Approved Medicine for Recurrent Low-Grade Interme
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Monday, 11'th May 2026
From a technical perspective, Urogen Pharma (URGN) is looking like an interesting pick, as it just reached a key level of support. URGN's 50-day simple moving average crossed above its 200-day simple
UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027
03:59pm, Thursday, 07'th May 2026
UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more than doubled QoQ to $29.2M, driven by the January J
